PMID: 2510039Sep 1, 1989Paper

Zeroing in on amyloid proteins in Alzheimer disease therapy

Neurobiology of Aging
B W Festoff

Abstract

The authors have provided us with a complete review of the approaches to the amyloid proteins of Alzheimer's disease in regards to targets for drug therapy. Sufficient information is now available concerning systemic amyloidogenesis, genes for familial Alzheimer's disease and the beta amyloid precursor protein, as well as the posttranslational processing requirements for amyloidogenesis and its prevention. Recent excitement concerning the roles for serine proteases and their inhibitors, both in the production and prevention of amyloidogenesis, make this review and its publication in the Neurobiology of Aging extremely timely.

References

Feb 11, 1988·Nature·R W Carrell
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D Gurwitz, D D Cunningham
Dec 9, 1988·Science·R L StornettaK R Lynch
Feb 1, 1988·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·D R Boswell, R W Carrell

❮ Previous
Next ❯

Citations

Jan 1, 1994·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·G J HoB W Festoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.